The ability to overcome multidrug resistance of tumour cell lines by novel acridine cytostatics with condensed heterocyclic rings

• Autorzy: Bontemps-Gracz M. M. , Kupiec A. , Antonini I. , Borowski E.
• Języki publikacji: EN

Abstrakty

EN

Two recently synthesized groups of acridine cytostatics containing fused hetero­cyclic ring(s): pyrazoloacridines (PAC) and pyrazolopyrimidoacridines (PPAC) were tested in regard to their in vitro cytotoxic activity towards a panel of sensitive and re­sistant human tumor cell lines. The obtained results corroborate our earlier hypothe­sis on the essential role of heterocyclic ring fused to the acridine moiety in the ability of acridine cytostatics to overcome multidrug resistance of tumor cells. The presence, location and kind of substituents considerably influenced both the cytotoxic activity of the derivatives and their ability to overcome multidrug resistance. The same factors also affected the cytostatics ability to differentiate between tumor cell lines with vari­ous types of drug exporting pumps.

Słowa kluczowe

EN

tumour cell line; multidrug resistance; cytotoxic activity; acridine cytostatics; man; pyrazoloacridine; tumour cell; antitumour compound; pyrazolopyrimidoacridine

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2002
• Tom: 49
• Numer: 1
• Opis fizyczny: p.87-92,fig.

Twórcy

autor

Bontemps-Gracz M. M.

• Technical University of Gdansk, Gdansk, Poland

autor

Kupiec A.

autor

Antonini I.

autor

Borowski E.

Bibliografia

• 1. Dicato, M., Duhem, C., Pauly, M. & Ries, F. (1997) Multidrug resistance: Molecular and clinical aspects. Cytokines Cell. Mol. Ther. 3, 91-99.
• 2. Ling, V. (1997) Multidrug resistance: Molecular mechanisms and clinical relevance. Cancer Chemother. Pharmacol. 40(Suppl), S3-S8.
• 3. van den Heuvel-Eibrink, M.M., Sonneveld, P. & Pieters, R. (2000) The prognostic significance of membrane-transport- associated multidrug resistance (MDR) proteins in leukemia. Int. J. Clin. Pharmacol. Therapeut. 38, 94-110.
• 4. Stefanska, B., Dzieduszycka, M., Bontemps- Gracz, M.M., Borowski, E., Martelli, S., Supino, R., Pratesi, G., De Cesare, M.A., Zunino, F., Kusnierczyk, H. & Radzikowski, C. (1999) 8,11-Dihydroxy-6-[(aminoalkyl)amino]- 7 H- benzo[e]perimidin-7-ones with activity in multidrug resistant cell lines; synthesis and antitumor evaluation. J. Med. Chem. 42, 3494-3501.
• 5. Tkaczyk-Gobis, K., Tarasiuk, J., Seksek, O., Stefanska, B., Borowski, E. & Garnier- Suillerot, A. (2000) Transport of new non- cross-resistant antitumor compounds of the benzoperimidine family in multidrug resistant cells. Eur. J. Pharmacol. 413, 131-141.
• 6. Bontemps-Gracz, M.M. (2000) Aktywnosc cytotoksyczna nowych pochodnych i analogow antrachinonu oraz zwiazkow pokrewnych z grupy akrydyny ze szczegolnym uwzglednieniem komorek nowotworowych z indukowana krzyzowa opornoscia wielolekowa. (The cytotoxic activity of novel derivatives and analogues ofanthraquinone and related acridine compounds with particular emphasis on tumor cell lines with induced multidrug cross-resistance.) Ph.D. Thesis, Gdansk, 2000 (in Polish).
• 7. Antonini, I., Polucci, P. & Martelli, S. (1999) Preparation of pyrazoloacridines and pyrazolopyrimidoacridines as antitumor agents. PCT Int. Appl. WO 9906405, Chem. Abstr. 130, 153666.
• 8. Antonini, I., Polucci, P., Magnano, A. & Martelli, S. (2001) Synthesis, antitumor cytotoxicity, and DNA-binding of novel N-5,2-di- (omega -aminoalkyl)-2,6-dihydropyrazolo[3,4,5-k/j- acridine-5-carboxamides. J. Med. Chem. 44, 3329-3333.
• 9. Antonini, I., Polucci, P., Magnano, A., Gatto, B., Palumbo, M., Menta, E., Pescalli, N. & Martelli, S. (2002) 2,6- Di(omega-aminoalkyl) -2 2,5,6,7-tetrahydropyrazolo[3,4,5-mn]pyrimido- [5,6,1-de]acridine-5,7-diones: Novel, potent, cytotoxic, and DNA-binding agents . J. Med. Chem. (in press).